Biomarkers for insulin resistance and inflammation and the risk for all-cause dementia and Alzheimer disease

Results from the Framingham Heart Study

Thomas M. Van Himbergen, Alexa S. Beiser, Masumi Ai, Sudha Seshadri, Seiko Otokozawa, Rhoda Au, Nuntakorn Thongtang, Philip A. Wolf, Ernst J. Schaefer

Research output: Contribution to journalArticle

103 Citations (Scopus)

Abstract

Objective: To investigate the contribution of biomarkers of glucose homeostasis (adiponectin, glucose, glycated albumin, and insulin levels) and inflammation (high-sensitivity C-reactive protein and lipoprotein-associated phospholipase A2 levels) to the risk of developing Alzheimer disease (AD) and all-cause dementia. Design: Prospective cohort study. Setting: Dementia-free Framingham Heart Study participants had sera measured for these biomarkers at the 19th biennial examination (1985-1988) and were followed up prospectively for the development of AD and all-cause dementia. Participants: Eight hundred forty (541 women, median age of 76 years) subjects participated in the study. Main Outcome Measures: We used sex-pooled and sex-specific multivariable Cox proportional hazards models adjusted for age, education, body mass index, recent change in weight, APOE ε4 allele status, and plasma docosahexaenoic acid levels to determine association of these biomarkers with the development of all-cause dementia and AD. Results: Over a mean follow-up period of 13 years, 159 persons developed dementia (including 125 with AD). After adjustment for other risk factors, only adiponectin in women was associated with an increased risk of all-cause dementia (hazard ratio [HR], 1.29; 95% confidence interval [CI], 1.00-1.66; P=.054) and AD (HR, 1.33; 95% CI, 1.00-1.76; P=.050) per 1-SD increase in adiponectin level. Women with baseline adiponectin values more than the median had a higher risk of all-cause dementia (HR, 1.63; 95% CI, 1.03-2.56; P=.04) and AD (HR, 1.87; 95% CI, 1.13-3.10; P=.01) as compared with those with values less than the median. Conclusion: In women, increased plasma adiponectin levels are an independent risk factor for the development of both all-cause dementia and AD.

Original languageEnglish (US)
Pages (from-to)594-600
Number of pages7
JournalArchives of Neurology
Volume69
Issue number5
DOIs
StatePublished - May 1 2012
Externally publishedYes

Fingerprint

Dementia
Insulin Resistance
Alzheimer Disease
Biomarkers
Adiponectin
Inflammation
Confidence Intervals
1-Alkyl-2-acetylglycerophosphocholine Esterase
Glucose
Insulin
Alzheimer's Disease
Causes
Docosahexaenoic Acids
Proportional Hazards Models
C-Reactive Protein
Body Mass Index
Homeostasis
Cohort Studies
Alleles
Outcome Assessment (Health Care)

ASJC Scopus subject areas

  • Arts and Humanities (miscellaneous)
  • Clinical Neurology

Cite this

Biomarkers for insulin resistance and inflammation and the risk for all-cause dementia and Alzheimer disease : Results from the Framingham Heart Study. / Van Himbergen, Thomas M.; Beiser, Alexa S.; Ai, Masumi; Seshadri, Sudha; Otokozawa, Seiko; Au, Rhoda; Thongtang, Nuntakorn; Wolf, Philip A.; Schaefer, Ernst J.

In: Archives of Neurology, Vol. 69, No. 5, 01.05.2012, p. 594-600.

Research output: Contribution to journalArticle

Van Himbergen, Thomas M. ; Beiser, Alexa S. ; Ai, Masumi ; Seshadri, Sudha ; Otokozawa, Seiko ; Au, Rhoda ; Thongtang, Nuntakorn ; Wolf, Philip A. ; Schaefer, Ernst J. / Biomarkers for insulin resistance and inflammation and the risk for all-cause dementia and Alzheimer disease : Results from the Framingham Heart Study. In: Archives of Neurology. 2012 ; Vol. 69, No. 5. pp. 594-600.
@article{c06b5fc39a2d457f8d8bb657472ac9fa,
title = "Biomarkers for insulin resistance and inflammation and the risk for all-cause dementia and Alzheimer disease: Results from the Framingham Heart Study",
abstract = "Objective: To investigate the contribution of biomarkers of glucose homeostasis (adiponectin, glucose, glycated albumin, and insulin levels) and inflammation (high-sensitivity C-reactive protein and lipoprotein-associated phospholipase A2 levels) to the risk of developing Alzheimer disease (AD) and all-cause dementia. Design: Prospective cohort study. Setting: Dementia-free Framingham Heart Study participants had sera measured for these biomarkers at the 19th biennial examination (1985-1988) and were followed up prospectively for the development of AD and all-cause dementia. Participants: Eight hundred forty (541 women, median age of 76 years) subjects participated in the study. Main Outcome Measures: We used sex-pooled and sex-specific multivariable Cox proportional hazards models adjusted for age, education, body mass index, recent change in weight, APOE ε4 allele status, and plasma docosahexaenoic acid levels to determine association of these biomarkers with the development of all-cause dementia and AD. Results: Over a mean follow-up period of 13 years, 159 persons developed dementia (including 125 with AD). After adjustment for other risk factors, only adiponectin in women was associated with an increased risk of all-cause dementia (hazard ratio [HR], 1.29; 95{\%} confidence interval [CI], 1.00-1.66; P=.054) and AD (HR, 1.33; 95{\%} CI, 1.00-1.76; P=.050) per 1-SD increase in adiponectin level. Women with baseline adiponectin values more than the median had a higher risk of all-cause dementia (HR, 1.63; 95{\%} CI, 1.03-2.56; P=.04) and AD (HR, 1.87; 95{\%} CI, 1.13-3.10; P=.01) as compared with those with values less than the median. Conclusion: In women, increased plasma adiponectin levels are an independent risk factor for the development of both all-cause dementia and AD.",
author = "{Van Himbergen}, {Thomas M.} and Beiser, {Alexa S.} and Masumi Ai and Sudha Seshadri and Seiko Otokozawa and Rhoda Au and Nuntakorn Thongtang and Wolf, {Philip A.} and Schaefer, {Ernst J.}",
year = "2012",
month = "5",
day = "1",
doi = "10.1001/archneurol.2011.670",
language = "English (US)",
volume = "69",
pages = "594--600",
journal = "Archives of Neurology",
issn = "0003-9942",
publisher = "American Medical Association",
number = "5",

}

TY - JOUR

T1 - Biomarkers for insulin resistance and inflammation and the risk for all-cause dementia and Alzheimer disease

T2 - Results from the Framingham Heart Study

AU - Van Himbergen, Thomas M.

AU - Beiser, Alexa S.

AU - Ai, Masumi

AU - Seshadri, Sudha

AU - Otokozawa, Seiko

AU - Au, Rhoda

AU - Thongtang, Nuntakorn

AU - Wolf, Philip A.

AU - Schaefer, Ernst J.

PY - 2012/5/1

Y1 - 2012/5/1

N2 - Objective: To investigate the contribution of biomarkers of glucose homeostasis (adiponectin, glucose, glycated albumin, and insulin levels) and inflammation (high-sensitivity C-reactive protein and lipoprotein-associated phospholipase A2 levels) to the risk of developing Alzheimer disease (AD) and all-cause dementia. Design: Prospective cohort study. Setting: Dementia-free Framingham Heart Study participants had sera measured for these biomarkers at the 19th biennial examination (1985-1988) and were followed up prospectively for the development of AD and all-cause dementia. Participants: Eight hundred forty (541 women, median age of 76 years) subjects participated in the study. Main Outcome Measures: We used sex-pooled and sex-specific multivariable Cox proportional hazards models adjusted for age, education, body mass index, recent change in weight, APOE ε4 allele status, and plasma docosahexaenoic acid levels to determine association of these biomarkers with the development of all-cause dementia and AD. Results: Over a mean follow-up period of 13 years, 159 persons developed dementia (including 125 with AD). After adjustment for other risk factors, only adiponectin in women was associated with an increased risk of all-cause dementia (hazard ratio [HR], 1.29; 95% confidence interval [CI], 1.00-1.66; P=.054) and AD (HR, 1.33; 95% CI, 1.00-1.76; P=.050) per 1-SD increase in adiponectin level. Women with baseline adiponectin values more than the median had a higher risk of all-cause dementia (HR, 1.63; 95% CI, 1.03-2.56; P=.04) and AD (HR, 1.87; 95% CI, 1.13-3.10; P=.01) as compared with those with values less than the median. Conclusion: In women, increased plasma adiponectin levels are an independent risk factor for the development of both all-cause dementia and AD.

AB - Objective: To investigate the contribution of biomarkers of glucose homeostasis (adiponectin, glucose, glycated albumin, and insulin levels) and inflammation (high-sensitivity C-reactive protein and lipoprotein-associated phospholipase A2 levels) to the risk of developing Alzheimer disease (AD) and all-cause dementia. Design: Prospective cohort study. Setting: Dementia-free Framingham Heart Study participants had sera measured for these biomarkers at the 19th biennial examination (1985-1988) and were followed up prospectively for the development of AD and all-cause dementia. Participants: Eight hundred forty (541 women, median age of 76 years) subjects participated in the study. Main Outcome Measures: We used sex-pooled and sex-specific multivariable Cox proportional hazards models adjusted for age, education, body mass index, recent change in weight, APOE ε4 allele status, and plasma docosahexaenoic acid levels to determine association of these biomarkers with the development of all-cause dementia and AD. Results: Over a mean follow-up period of 13 years, 159 persons developed dementia (including 125 with AD). After adjustment for other risk factors, only adiponectin in women was associated with an increased risk of all-cause dementia (hazard ratio [HR], 1.29; 95% confidence interval [CI], 1.00-1.66; P=.054) and AD (HR, 1.33; 95% CI, 1.00-1.76; P=.050) per 1-SD increase in adiponectin level. Women with baseline adiponectin values more than the median had a higher risk of all-cause dementia (HR, 1.63; 95% CI, 1.03-2.56; P=.04) and AD (HR, 1.87; 95% CI, 1.13-3.10; P=.01) as compared with those with values less than the median. Conclusion: In women, increased plasma adiponectin levels are an independent risk factor for the development of both all-cause dementia and AD.

UR - http://www.scopus.com/inward/record.url?scp=84860903756&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84860903756&partnerID=8YFLogxK

U2 - 10.1001/archneurol.2011.670

DO - 10.1001/archneurol.2011.670

M3 - Article

VL - 69

SP - 594

EP - 600

JO - Archives of Neurology

JF - Archives of Neurology

SN - 0003-9942

IS - 5

ER -